Single-antibody, targeted nanoparticle delivery of camptothecin

Molecular Pharmaceutics

Volumn 10, Issue 7, 2013, Pages 2558-2567

  Han, Han ^a   Davis, Mark E ^a  

^a California Institute of Technology   (United States)

Author keywords

antitumor efficacy; biodistribution; camptothecin; Herceptin; targeted nanoparticles

Indexed keywords

ANTIBODY; BORONIC ACID DERIVATIVE; CAMPTOTHECIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IRINOTECAN; NANOPARTICLE; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER REGRESSION; CANCER THERAPY; COMPARATIVE STUDY; CONJUGATE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; ZETA POTENTIAL;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; FEMALE; HUMANS; MICE; MICE, NUDE; NANOPARTICLES; POLYMERS; SUGAR ACIDS;

EID: 84879713300     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300702x     Document Type: Article

References (44)

1. Hsiang, Y. H.; Hertzberg, R.; Hecht, S.; Liu, L. F. Camptothecin Induces Protein-Linked DNA Breaks Via Mammalian DNA Topoisomerase-I J. Biol. Chem. 1985, 260, 4873-4878
2. Rapisarda, A.; Uranchimeg, B.; Scudiero, D. A.; Selby, M.; Sausville, E. A.; Shoemaker, R. H.; Melillo, G. Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway Cancer Res. 2002, 62, 4316-4324
3. Moertel, C. G.; Schutt, A. J.; Reitemeier, R. J.; Hahn, R. G. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer Cancer Chemother. Rep. 1972, 56, 95-101
4. Muggia, F. M.; Selawry, O. S.; Hansen, H. H.; Creaven, P. J.; Cohen, M. H. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies Cancer Chemother. Rep. 1972, 56, 515-521
5. Mi, Z. H.; Burke, T. G. Marked Interspecies Variations Concerning the Interactions of Camptothecin with Serum Albumins-A Frequency-Domain Fluorescence Spectroscopic Study Biochemistry 1994, 33, 12540-12545
6. Xu, Y.; Villalona-Calero, M. A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Ann. Oncol. 2002, 13, 1841-1851
7. Mathijssen, R. H. J.; van Alphen, R. J.; Verweij, J.; Loos, W. J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11) Clin. Cancer Res. 2001, 7 (8) 2182-2194
8. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokoyama, A.; Saitoh, S.; Shimokata, K.; Hasegawa, Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis Cancer Res. 2000, 60, 6921-6926
9. Tian, Q.; Zhang, J.; Chan, S. Y.; Tan, T. M. C.; Duan, W.; Huang, M.; Zhu, Y. Z.; Chan, E.; Yu, Q.; Nie, Y. Q.; Ho, P. C. L.; Li, Q.; Ng, K. Y.; Yang, H. Y.; Wei, H.; Bian, J. S.; Zhou, S. F. Topotecan is a substrate for multidrug resistance associated protein 4 Curr. Drug Metab. 2006, 7, 105-116
10. Svenson, S.; Wolfgang, M.; Hwang, J.; Ryan, J.; Eliasof, S. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101 J. Controlled Release 2011, 153, 49-55
11. Homsi, J.; Simon, G. R.; Garrett, C. R.; Springett, G.; De Conti, R.; Chiappori, A.; Munster, P. N.; Burton, M. K.; Stromatt, S.; Allievi, C.; Angiulli, P.; Eisenfeld, A.; Sullivan, D. M.; Daud, A. I. Phase I trial of poly-L-glutamate camptothecin (CT-2106) administered weekly in patients with advanced solid malignancies Clin. Cancer Res. 2007, 13, 5855-5861
12. Yurkovetskiy, A. V.; Fram, R. J. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer Adv. Drug Delivery Rev. 2009, 61, 1193-1202
13. Scott, L.; Yao, J.; Benson, A. B.; Thomas, A.; Falk, S.; Mena, R.; Picus, J.; Wright, J.; Mulcahy, M.; Ajani, J.; Evans, T. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma Cancer Chemother. Pharm. 2009, 63, 363-370
14. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review J. Controlled Release 2000, 65, 271-284
15. Kirpotin, D. B.; Drummond, D. C.; Shao, Y.; Shalaby, M. R.; Hong, K. L.; Nielsen, U. B.; Marks, J. D.; Benz, C. C.; Park, J. W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res. 2006, 66, 6732-6740
16. Bartlett, D. W.; Su, H.; Hildebrandt, I. J.; Weber, W. A.; Davis, M. E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 15549-15554
17. Choi, C. H. J.; Alabi, C. A.; Webster, P.; Davis, M. E. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 1235-1240
18. Scott, A. M.; Wolchok, J. D.; Old, L. J. Antibody therapy of cancer Nat. Rev. Cancer 2012, 12, 278-287
19. Janthur, W. D.; Cantoni, N.; Mamot, C. Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice Int. J. Mol. Sci. 2012, 13, 16020-16045
20. Luedke, E.; Jaime-Ramirez, A. C.; Bhave, N.; Carson, W. E. Monoclonal Antibody Therapy of Pancreatic Cancer With Cetuximab: Potential for Immune Modulation J. Immunother. 2012, 35, 367-373
21. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; Mcguire, W. L. Human-Breast Cancer-Correlation of Relapse and Survival with Amplification of the Her-2 Neu Oncogene Science 1987, 235, 177-182
22. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A.; Press, M. F. Studies of the Her-2/Neu Proto-Oncogene in Human-Breast and Ovarian-Cancer Science 1989, 244, 707-712
23. Slamon, D. J.; Leyland-Jones, B.; Shak, S.; Fuchs, H.; Paton, V.; Bajamonde, A.; Fleming, T.; Eiermann, W.; Wolter, J.; Pegram, M.; Baselga, J.; Norton, L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 2001, 344, 783-792
24. Smith, I.; Procter, M.; D Gelber, R.; Guillaume, S.; Feyereislova, A.; Dowsett, M.; Goldhirsch, A.; Untch, M.; Mariani, G.; Baselga, J.; Kaufmann, M.; Cameron, D.; Bell, R.; Bergh, J.; Coleman, R.; Wardley, A.; Harbeck, N.; Lopez, R. I.; Mallmann, P.; Gelmon, K.; Wilcken, N.; Wist, E.; Rovira, P. S.; Piccart-Gebhart, M. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 2007, 369, 29-36
25. Cobleigh, M. A.; Vogel, C. L.; Tripathy, D.; Robert, N. J.; Scholl, S.; Fehrenbacher, L.; Wolter, J. M.; Paton, V.; Shak, S.; Lieberman, G.; Slamon, D. J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J. Clin. Oncol. 1999, 17, 2639-2648
26. Vogel, C. L.; Cobleigh, M. A.; Tripathy, D.; Gutheil, J. C.; Harris, L. N.; Fehrenbacher, L.; Slamon, D. J.; Murphy, M.; Novotny, W. F.; Burchmore, M.; Shak, S.; Stewart, S. J.; Press, M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J. Clin. Oncol. 2002, 20, 719-726
27. Casi, G.; Neri, D. Antibody-drug conjugates: Basic concepts, examples and future perspectives J. Controlled Release 2012, 161, 422-428
28. Adair, J. R.; Howard, P. W.; Hartley, J. A.; Williams, D. G.; Chester, K. A. Antibody-drug conjugates-a perfect synergy Expert Opin. Biol. Ther. 2012, 12, 1191-1206
29. Younes, A.; Yasothan, U.; Kirkpatrick, P. Brentuximab vedotin Nat. Rev. Drug Discovery 2012, 11, 19-20
30. Katz, J.; Janik, J. E.; Younes, A. Brentuximab Vedotin (SGN-35) Clin. Cancer Res. 2011, 17, 6428-6436
31. Younes, A.; Gopal, A. K.; Smith, S. E.; Ansell, S. M.; Rosenblatt, J. D.; Savage, K. J.; Ramchandren, R.; Bartlett, N. L.; Cheson, B. D.; de Vos, S.; Forero-Torres, A.; Moskowitz, C. H.; Connors, J. M.; Engert, A.; Larsen, E. K.; Kennedy, D. A.; Sievers, E. L.; Chen, R. Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma J. Clin. Oncol. 2012, 30, 2183-2189
32. Pro, B.; Advani, R.; Brice, P.; Bartlett, N. L.; Rosenblatt, J. D.; Illidge, T.; Matous, J.; Ramchandren, R.; Fanale, M.; Connors, J. M.; Yang, Y.; Sievers, E. L.; Kennedy, D. A.; Shustov, A. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study J. Clin. Oncol. 2012, 30, 2190-2196
33. Phillips, G. D. L.; Li, G. M.; Dugger, D. L.; Crocker, L. M.; Parsons, K. L.; Mai, E.; Blattler, W. A.; Lambert, J. M.; Chari, R. V. J.; Lutz, R. J.; Wong, W. L. T.; Jacobson, F. S.; Koeppen, H.; Schwall, R. H.; Kenkare-Mitra, S. R.; Spencer, S. D.; Sliwkowski, M. X. Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate Cancer Res. 2008, 68, 9280-9290
34. Verma, S.; Miles, D.; Gianni, L.; Krop, I. E.; Welslau, M.; Baselga, J.; Pegram, M.; Oh, D. Y.; Dieras, V.; Guardino, E.; Fang, L.; Lu, M. W.; Olsen, S.; Blackwell, K. Trastuzumab emtansine for HER2-positive advanced breast cancer N. Engl. J. Med. 2012, 367, 1783-91
35. Hamblett, K. J.; Senter, P. D.; Chace, D. F.; Sun, M. M. C.; Lenox, J.; Cerveny, C. G.; Kissler, K. M.; Bernhardt, S. X.; Kopcha, A. K.; Zabinski, R. F.; Meyer, D. L.; Francisco, J. A. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate Clin. Cancer Res. 2004, 10, 7063-7070
36. Drummond, D. C.; Noble, C. O.; Guo, Z.; Hayes, M. E.; Connolly-Ingram, C.; Gabriel, B. S.; Hann, B.; Liu, B.; Park, J. W.; Hong, K.; Benz, C. C.; Marks, J. D.; Kirpotin, D. B. Development of a highly stable and targetable nanoliposomal formulation of topotecan J. Controlled Release 2010, 141, 13-21
37. Yang, T.; Choi, M. K.; Cui, F. D.; Kim, J. S.; Chung, S. J.; Shim, C. K.; Kim, D. D. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome J. Controlled Release 2007, 120, 169-177
38. Cirstoiu-Hapca, A.; Buchegger, F.; Lange, N.; Bossy, L.; Gurny, R.; Delie, F. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: Therapeutic efficacy and biodistribution in mice J. Controlled Release 2010, 144, 324-331
39. Hong, M. H.; Zhu, S. J.; Jiang, Y. Y.; Tang, G. T.; Pei, Y. Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin J. Controlled Release 2009, 133, 96-102
40. Han, H.; Davis, M. E. Targeted nanoparticles assembled via complexation of boronic acid-containing targeting moieties to diol-containing polymers Bioconjugate Chem. 2013, 24, 669-677
41. Supko, J. G.; Malspeis, L. Pharmacokinetics of the 9-Amino and 10,11-Methylenedioxy Derivatives of Camptothecin in Mice Cancer Res. 1993, 53, 3062-3069
42. Cheng, W. W. K.; Allen, T. M. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: A comparison of whole monoclonal antibody, Fab' fragments and single chain Fv J. Controlled Release 2008, 126, 50-58
43. Davis, P. L.; Shaiu, W. L.; Scott, G. L.; Iglehart, J. D.; Hsieh, T. S.; Marks, J. R. Complex response of breast epithelial cell lines to topoisomerase inhibitors Anticancer Res. 1998, 18, 2919-2932
44. Gakhar, G.; Wight-Carter, M.; Andrews, G.; Olson, S.; Nguyen, T. A. Hydronephrosis and urine retention in estrogen-implanted athymic nude mice Vet. Pathol. 2009, 46, 505-8